TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01330602

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMPRESS intervention
Description: The key elements of the IMPRESS intervention include:~* Promoting a healthy lifestyle~* Supporting lifestyle and risk modification~* Encouraging active self-management of risk and chronic disease~* Improving coordination of care~* Pharmacological therapy
Study: NCT03790670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Recombinant human GM-CSF produced by recombinant DNA technology using a yeast (S. cerevisiae) expression system
Study: NCT02526368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C-Pyruvate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C,15N2-urea
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Undergo MRSI
Study: NCT01782625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NO exercise at depth
Description: Subjects will NOT exercise while at depth

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NO exercise at depth
Description: Subjects will NOT exercise while at depth

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise at depth
Description: Subjects will exercise while at depth

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise at depth
Description: Subjects will exercise while at depth
Study: NCT02300038

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine (Xylocaine)
Description: perineuromally administration of 1 ml lidocaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine (Xylocaine)
Description: perineuromally administration of 1 ml lidocaine
Study: NCT04195399

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirogacestat
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray
Study: NCT02300038

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NaCl
Description: perineuromally administration of NaCL

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: perineuromally administration of NaCL
Study: NCT04292262

Intervention type: OTHER
Intervention: Observational
Description: Observational

Intervention type: OTHER
Intervention: Observational
Description: Observational
Study: NCT00650325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline Hydrochloride Tablets 100 mg
Description: 100mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoloft® Tablets 100 mg
Description: 100mg, single dose fasting
Study: NCT03383835

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Supplementation
Description: DHA 600 milligrams (mg) per day for 6 months~EPA 300mg per day for 6 months
Study: NCT03566914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 MG
Description: Tadalafil 10 mg per oral once daily for 3 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TPlacebo tablet per oral once daily for 3 months
Study: NCT00474045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Treat-to-target, dose titration, s.c. (under the skin) injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH insulin
Description: Treat-to-target, dose titration, s.c. (under the skin) injection
Study: NCT02073097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV, according to dose level. Cohorts begin with dose level (DL)1, escalated in standard 3+3 design to identify a recommended phase 2 dose DL (-2) 11 mg/m2 on day 1 and 2 every 21 days, cycles 1-6~DL (-1) 15 mg/m2 on days 1 and 2 every 21 days, cycles 1-6~DL (1) 20 mg/m2 days 1,2 every 21 days, cycles 1-6~DL (2) 20 mg/m2 days 1,2 of cycle 1 followed by 27 mg/m2 days 1,2 every 21 days for cycles 2-6.~DL (3) 20 mg/m2 days 1,2 of cycle 1 followed by 36 mg/m2 days 1,2 every 21 days for cycles 2-6.~DL(4) 20 mg/m2 days 1,2 of cycle 1 followed by 45 mg/m2 days 1,2 every 21 days for cycles 2-6~DL (5) 20 mg/m2 days 1,2 of cycle 1 followed by 56 mg/m2 days 1,2 every 21 days for cycles 2-6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV (375mg/m\^2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV (750mg/m\^2)
Study: NCT00474045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Treat-to-target, dose titration, s.c. (under the skin) injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Treat-to-target, dose titration, s.c. (under the skin) injection
Study: NCT02219789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Given PO
Study: NCT02073097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride
Description: Given IV (50mg/m\^2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine sulfate
Description: Given IV (1.4mg/m\^2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO (100mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg SC day 4 (every 21 days). Filgrastim 300 or 480 mcg IV/SC daily days 1-10 may be substituted if pegfilgrastim is not available. ONPROTM is also an acceptable method of administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Description: PO (400mg)
Study: NCT02219789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03291522

Intervention type: PROCEDURE
Intervention: Ultrasound-guided rete testis flushing and aspiration
Description: Ultrasound-guided rete testis flushing and aspiration is performed first. If no sperm is found, the patient can choose to do a standard of care procedure (but not required).
Study: NCT04256421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab 600 milligrams (mg) administered by IV infusion on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg administered by IV infusion on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg administered by IV infusion on Day 1 of each 21-day cycle.
Study: NCT01058993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100 or plerixafor
Description: The study will examine the hematological effects/safety of plerixafor in patients with myelokathexis attributable to mutations of CXCR4. Plerixafor will be administered on days 1, 3, 5, 8, and 10. Five intrapatient escalating doses of AMD 3100, 20 micrograms per kilogram (mcg/kg), 40 micrograms per kilogram (mcg/kg), 80 micrograms per kilogram (mcg/kg), and 240 micrograms per kilogram (mcg/kg) will be examined in the patients at University of Washington General Clinical Research Center for up to 10 days, requiring subjects be available up to 14 days. Patients will be monitored for hematological effects of plerixafor and observed for adverse effects. If normal blood neutrophil count is achieved and maintained for at least 24 hours prior to highest dose, we will stop at that level.
Study: NCT01470625

Intervention type: OTHER
Group type: OTHER
Intervention: LCP Program
Description: The LCP Program is continuous quality improvement program of end-of-life care implemented in hospice
Study: NCT00941499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAI Oxaliplatin
Description: 140 mg/m\^2 by HAI (hepatic arterial infusion)over 2 hours on Day 1 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAI Oxaliplatin
Description: 140 mg/m\^2 by HAI (hepatic arterial infusion)over 2 hours on Day 1 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAI Oxaliplatin
Description: 140 mg/m\^2 by HAI (hepatic arterial infusion)over 2 hours on Day 1 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAI Oxaliplatin
Description: 140 mg/m\^2 by HAI (hepatic arterial infusion)over 2 hours on Day 1 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 900-1750 mg/m\^2 HAI infusion over 24 hours on Days 1 - 2 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/Kg by vein on Day 1 of 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/Kg by vein on Day 1 of 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/Kg by vein on Day 1 of 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Loading dose of 250-500mg/m\^2 and Maintenance dose of 125-250 mg/m\^2 by vein on Day 1 of 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200 mg/m\^2 by vein on Days 1 and 2 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 300-400 mg/m\^2 bolus + 600-1000 mg/m\^2 infusion over 22 hours on Days 1-2 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5 - 15 mg/Kg by vein on Day 1 of 21 day cycle.
Study: NCT02438826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab 300 mg
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Galcanezumab 300 mg
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT04486053

Intervention type: OTHER
Intervention: Screening
Description: The patients who agreed to participate to the study were assessed with a survey which included age, gender, height, weight and hand dominancy questions. Sensory, motor and functional assessments of the bilateral hand were performed.
Study: NCT04256421

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin was administered by IV infusion on Day 1 of each 21-day cycle for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was administered by IV infusion on Day 1 of each 21-day cycle for 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide 100 mg/m\^2 administered by IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100 mg/m\^2 administered by IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles.
Study: NCT04437368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT005; Low Dose
Description: Part 1 of the study will test two doses of GT005: Low Dose and High Dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT005; High Dose
Description: Part 1 of the study will test two doses of GT005: Low Dose and High Dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT005; Low Dose
Description: Part 2 of the study will test one dose: Low Dose.
Study: NCT04256421

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo administered by IV infusion on Day 1 of each 21-day cycle.
Study: NCT01546467

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Description: Cognitive remediation including feedback from neurocognitive assessment, psychoeducation about cognitive deficits, 30 hours of computer based drill and practise and strategy coaching based cognitive remediation, 1-3 collaborative meetings with cognitive specialist, participant, therapist and teacher, occupational therapist or other therapist (depending on participants rehabilitation situation) to enhance transfer of skills to daily functioning
Study: NCT00965926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178
Description: oral
Study: NCT00385411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valproate microgranules
Description: 20 to 30 mg/kg/day
Study: NCT01995539

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: therapy regimen
Description: Subjects will be recommend changes in therapy regimens.
Study: NCT05271058

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: 23 eyes that didn't receive any intraoperative steroids

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone group
Description: 23 eyes each received intracameral dexamethasone at the conclusion of phacoemulsification Received intracameral 0.4 mg in / 0.1 ml dexamethasone (8mg/2ml®; Amriya or Epico) at the end of phacoemulsification.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone (TA) group
Description: 23 eyes each received intracameral triamcinolone (TA) at the conclusion of phacoemulsification Received intracameral 2 mg/0.05 ml triamcinolone (TA) (Kenacort-A®; Bristol-Myers Squibb) at the end of phacoemulsification.
Study: NCT04274270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: Radiotherapy was performed with a cyberknife or accelerator stereotactic radiotherapy, which lasted 3-10 days.After the end of radiotherapy,S1 60mg, BID, day 1-28, as taken orally, and repeated every 6 weeks, with concurrent Endostar therapy: 210mg was used by intravenous infusion for 7 consecutive days during each cycle of chemotherapy, and 30mg was used every 24 hours.
Study: NCT00889057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: 400 mg bid until progression or inacceptable toxicity
Study: NCT02368106

Intervention type: RADIATION
Intervention: Radiation Therapy
Description: targeted radiation treatment
Study: NCT03046615

Intervention type: DEVICE
Intervention: EEG Electrode Patch
Description: The additional electrodes are modified EEG electrodes (used in clinical practice on the head already) placed in a silicone molding. These are placed lateral to the eye with the patient asleep. These are then wired to the same recording apparatus that we would commonly use for recording.

Intervention type: DEVICE
Intervention: Standard Needles
Description: Needles are placed in the muscles surrounding the eye to measure eye movements.
Study: NCT04563650

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood sample
Description: Sample collection of 4 to 10 tubes of whole blood will be done according to centre Saint-Victor's protocol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: Sample collection of 4 to 10 tubes of whole blood will be done according to centre Saint-Victor's protocol.
Study: NCT01719107

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L. reuteri DSM 17938 chewable tablets
Description: 2 chewable tablets with breakfast for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo chewable tablets
Description: 2 chewable tablets with breakfast for 4 weeks
Study: NCT01885728

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: An arginine rich nutritional supplement
Description: Impact is a nutritional supplement formulated with 18 grams of protein per serving and 24 essential nutrients including arginine.
Study: NCT01308606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 HPMC capsule
Description: Single intake of one 150-mg capsule without food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 HPMC or gelatin capsule
Description: Single intake of one 150-mg capsule after high-fat breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 HPMC or gelatin capsule
Description: Single intake of one 150-mg capsule without food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 HPMC or gelatin capsule
Description: Single intake of one 150-mg capsule after standardized breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 gelatin capsule
Description: Single intake of one 150-mg capsule without food
Study: NCT01720732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifeline NET
Description: Short Version of Narrative Exposure Therapy
Study: NCT01936896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha 1-Antitrypsin
Study: NCT02309437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Use oxycodone to treat patients with mild pain caused by radiation mucositis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Use oxycodone to treat patients with moderate/severe pain caused by radiation mucositis.
Study: NCT04007458

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Letter
Description: MaineGeneral Radiology will generate a reminder letter about their need for an annual low dose CT scan to the subjects in this arm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker Phone Call
Description: Patients will receive a phone call from community health worker, offering to help them overcome barriers to repeat annual screening and offering to help them schedule their screening.
Study: NCT03771014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early mobility
Description: This progressive mobility pathway commenced with passive cycling within 48 hours of intubation and ventilation and progressing through assisted cycling, active cycling, bed exercises, sitting, mobilising out of bed to walking
Study: NCT03725540

Intervention type: DEVICE
Intervention: I-gel
Description: Patients will be anesthetized using an appropriate sized I-gel mask according to the manufacturer's recommendations after lubrication with a water-soluble lubricant.

Intervention type: DEVICE
Intervention: Baska_mask
Description: Patients will be anesthetized using BASKA mask after lubrication with a water-soluble lubricant.
Study: NCT01704625

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: The investigators wish to see if emergency medicine physicians can use osteopathic evaluation and OMT to reliably treat headaches. The results of the examination and treatment will be recorded, but will not be used to change treatment or to change additional tests.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Osteopathic Manipulative Treatment
Description: The sham group will receive 3 sham treatments.
Study: NCT02042079

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EFTR with LA
Description: (Endoscopic full-thickness resection with laparoscopic assistance)
Study: NCT04547088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Anti-PD-1 targeted immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: A small-molecule vascular endothelial growth factors receptor (VEGFR) tyrosine kinase inhibitor
Study: NCT04418934

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemanext One
Description: Leukoreduced red blood cell product from donors in the Investigational Product arm will be processed in the Hemanext Oxygen Reduction Bag for 3 hours and then transferred to the Hemanext Storage Bag and stored for 56 days at 1-6°C.
Study: NCT03312153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neem
Description: A natural irrigant solution act as anti-inflammatory and anti bacterial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2.5% sodium hypochlorite
Description: anti bacterial root canal irrigant solution
Study: NCT01152775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: This group of patients will be exposed to multimedia
Description: This group of patients will be exposed to multimedia

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Media
Description: This group will not be exposed to multimedia
Study: NCT00838682

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole sodium IV
Description: Intravenous Omeprazole (brand name: Losec® injection 40 mg) 80 mg as a bolus injection followed by continuous infusion at 8 mg per hour for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Oral Rabeprazole 20 mg twice daily for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
Study: NCT01126827

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Cognitive Behavioral Therapy or Supportive Psychotherapy
Description: 12 weekly group therapy sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Cognitive Behavioral Therapy or Supportive Psychotherapy
Description: 12 weekly group therapy sessions
Study: NCT02472652

Intervention type: DRUG
Group type: OTHER
Intervention: Abilify Maintena
Description: For subjects who meet inclusion/exclusion criteria for this study a switch from Palliperidone Palmitate or Risperidone injectable will be made to Abilify Maintena for a 3 month period to determine if there are changes in sexual dysfunction ratings over this time period
Study: NCT03895164

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced NE
Description: Standard nutrition education package from primary health care enhanced with local specific food-based complementary feeding recommendation

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard NE
Description: Standard nutrition education package from primary health care
Study: NCT03464279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge using Behavioral Economic Interventions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Practices to Reduce Health System Antibiotic Prescription
Study: NCT02891538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate (EGCG)
Description: Teavigo™ is a natural, caffeine-free, highly purified and refined green tea extract providing 94% epigallocatechin gallate (EGCG).\*